Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCoca-cola Euro. Regulatory News (CCEP)

Share Price Information for Coca-cola Euro. (CCEP)

Share Price is delayed by 15 minutes
Get Live Data
7,420.00    35.00 (0.47%)
Bid:
7,425.00
Ask:
7,430.00
Spread: 5.00 (0.067%)
Market Cap: £32.85b
CCEP Live PriceLast checked at - London Stock Exchange

Intraday Coca-cola Euro. Share Chart

Transactions in Own Shares & Programme Update

23 May 2025 07:00

RNS Number : 8816J
Coca-Cola Europacific Partners plc
23 May 2025
 

 

Coca-Cola Europacific Partners plc (the "Company")Transactions in Own Shares and Programme Update

Repurchase of shares on 22 May 2025

The Company confirms that on 22 May 2025 it purchased a total of: (i) 30,719 ordinary shares of EUR 0.01 ("ordinary shares") on the US Trading Venues[1] and (ii) 0 ordinary shares on the London Trading Venues[2]; in both cases, from Goldman Sachs & Co. LLC, Goldman Sachs International or one of their affiliates, as detailed below.

The purchases form part of the Company's share buyback programme announced on 14 February 2025 (the "Programme"). In connection with the Programme, the Company expects to repurchase up to EUR 1 billion of ordinary shares (in aggregate).

All shares repurchased as part of the Programme have been or will be cancelled.

Programme update

The first tranche of the Programme, which the Company announced on 14 February 2025 (as updated on 28 March 2025 and 2 May 2025) and which had a maximum aggregate amount for purchases of €275,000,000, will be completed today. 

The second tranche of the Programme is expected to commence on 27 May 2025 and the Company has entered into an arrangement in relation to this second tranche with Goldman Sachs & Co. LLC and Goldman Sachs International, consisting of two contracts to enable the purchase of ordinary shares on both the US Trading Venues and the London Trading Venues. Share purchases will be made in accordance with the arrangement and made independently of and uninfluenced by the Company. The purpose of the Programme is to reduce the issued share capital of the Company. 

The second tranche of the Programme is expected to cover the period from 27 May 2025 until 7 August 2025. The maximum aggregate amount for purchases in respect of this second tranche of the Programme will be €205,000,000, of which up to €55,000,000 will be in respect of the London Trading Venues (with purchases on the London Trading Venues expected to be completed by 31 July 2025). 

Purchases pursuant to the second tranche of the Programme will be effected in accordance with (i) (in relation to purchases made on the London Trading Venues) the scope of the authority to repurchase ordinary shares "on market" conferred on the Company at the 2025 Annual General Meeting (ii) (in relation to purchases made on the US Trading Venues) the scope of the authority to repurchase ordinary shares "off market" conferred on the Company at the 2025 Annual General Meeting; (iii) (in relation to purchases made on the London Trading Venues) (EU) No 596/2014 (the Market Abuse Regulation) and the Commission Delegated Regulation (EU) 2016/1052 as applicable (both as in force in the UK, and as they form part of retained UK law as defined in the European Union (Withdrawal) Act 2018), (iv) Chapter 9 of the UK Listing Rules; and (v) applicable U.S. federal securities laws, including applicable US securities laws and anti-manipulation provisions thereof. In relation to purchases on the London Trading Venues, GS will acquire CREST depositary interests on the London Trading Venues, which will be cancelled together with the underlying shares they represent.

The maximum number of ordinary shares which may be purchased or committed to be purchased by the Company under the contracts entered into in respect of this second tranche of the Programme is 46,016,093 less such number of shares repurchased pursuant to the initial tranche of the Programme after 3 April 2025, which is the maximum number pursuant to the relevant authorities granted by shareholders at the Company's 2025 Annual General Meeting. 

Repurchase of shares on 22 May 2025

 

US Trading Venues

London Stock Exchange

CBOE Europe Limited

(CXE)

 

CBOE Europe Limited

(BXE)

Date of purchase

22 May 2025

22 May 2025

22 May 2025

22 May 2025

Aggregate number of ordinary shares purchased

30,719

0

0

0

Highest price paid (per ordinary share)

USD 89.2600

GBP 0

GBP 0

GBP 0

Lowest price paid (per ordinary share)

USD 88.3200

GBP 0

GBP 0

GBP 0

Volume weighted average price paid (per ordinary share)

USD 88.7229

GBP 0

GBP 0

GBP 0

 

This announcement does not constitute, or form part of, an offer or solicitation of an offer for securities in any jurisdiction.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), full details of the transactions, are set out in the Schedule to this announcement available through the link below:

http://www.rns-pdf.londonstockexchange.com/rns/8816J_1-2025-5-22.pdf

CONTACTS

Company Secretariat

Clare Wardle

clare.wardle@ccep.com

Investor Relations

Sarah Willett

sarah.willett@ccep.com

Media Relations

Shanna Wendt

mediaenquiries@ccep.com

 

ABOUT CCEP

Coca-Cola Europacific Partners is one of the world's leading consumer goods companies. We make, move and sell some of the world's most loved brands - serving nearly 600 million consumers and helping over 4 million customers across 31 countries grow.

We combine the strength and scale of a large, multi-national business with an expert, local knowledge of the customers we serve and communities we support.

The Company is currently listed on Euronext Amsterdam, NASDAQ, London Stock Exchange and on the Spanish Stock Exchanges, and a constituent of both the NASDAQ 100 and FTSE 100 indices, trading under the symbol CCEP.

For more information about CCEP, please visit www.cocacolaep.com and follow CCEP on LinkedIn

Cautionary note on forward-looking statements

This release contains statements, estimates or projections that constitute "forward-looking statements" concerning the financial condition, performance, results, guidance and outlook, dividends, consequences of mergers, acquisitions, joint ventures, divestitures, strategy and objectives of Coca-Cola Europacific Partners plc and its subsidiaries (together CCEP or the Group). Generally, the words "ambition", "target", "aim", "believe", "contemplate", "expect", "intend", "estimate", "anticipate", "project", "plan", "seek", "may", "could", "would", "should", "might", "will", "forecast", "outlook", "guidance", "possible", "potential", "predict", "objective" and similar expressions identify forward-looking statements, which generally are not historical in nature.

Forward-looking statements are subject to certain risks that could cause actual results to differ materially. Forward-looking statements are based upon various assumptions as well as CCEP's historical experience and present expectations or projections. As a result, undue reliance should not be placed on forward-looking statements, which speak only as of the date on which they are made. Factors that, in CCEP's view, could cause such actual results to differ materially from forward looking statements include, but are not limited to, those set forth in the "Risk Factors" section of CCEP's 2024 Annual Report on Form 20-F filed with the SEC on 21 March 2025 and subsequent filings.

 

 

 

 


[1] The "US Trading Venues" comprise Nasdaq and other applicable US trading venues.

[2] The "London Trading Venues" comprise the London Stock Exchange, CBOE Europe Limited (BXE) and CBOE Europe Limited (CXE). Goldman Sachs acquired CREST Depositary Interests on the London Trading Venues, which will be cancelled together with the underlying shares they represent.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSUUUARVBUVUUR
Date   Source Headline
12th Jun 20264:30 pmRNSDirector/PDMR Shareholding
5th Jun 20263:30 pmRNSDirector/PDMR Shareholding
3rd Jun 202612:30 pmRNSDirector/PDMR Shareholding
1st Jun 20261:30 pmRNSTotal Voting Rights
29th May 20261:00 pmRNSResult of AGM
21st May 20263:30 pmRNSDirector/PDMR Shareholding
18th May 202611:00 amRNSLetter to Shareholders
1st May 20264:15 pmRNSDirector/PDMR Shareholding
1st May 20261:30 pmRNSTotal Voting Rights
28th Apr 20267:00 amRNSQ1 Trading Update & Interim Dividend Declaration
27th Apr 20263:00 pmRNSTransactions in Own Shares
22nd Apr 20262:15 pmRNSDirector/PDMR Shareholding
20th Apr 20261:30 pmRNSTransactions in Own Shares
16th Apr 20269:15 amRNSNotice of AGM
15th Apr 202610:30 amRNSDirector/PDMR Shareholding
13th Apr 202612:30 pmRNSTransaction in Own Shares
10th Apr 202611:00 amRNSSID Appointment and Board Committee Changes
7th Apr 20262:00 pmRNSTransaction in Own Shares
1st Apr 20262:30 pmRNSTotal Voting Rights
1st Apr 202611:00 amRNSChange of Company Secretary
30th Mar 20263:30 pmRNSTransactions in Own Shares
27th Mar 20269:00 amRNSDirector/PDMR Shareholding
24th Mar 202612:00 pmRNSDirector/PDMR Shareholding
23rd Mar 20267:00 amRNSTransactions in Own Shares
20th Mar 20264:45 pmRNSDirector/PDMR Shareholding
20th Mar 20267:00 amRNSTransactions in Own Shares
19th Mar 20267:00 amRNSTransactions in Own Shares
18th Mar 20267:00 amRNSTransactions in Own Shares
17th Mar 20267:00 amRNSTransactions in Own Shares
17th Mar 20267:00 amRNSTransactions in Own Shares
16th Mar 20265:00 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTransactions in Own Shares
16th Mar 20267:00 amRNSTransactions in Own Shares
13th Mar 202612:11 pmRNSAnnual Financial Report
13th Mar 202612:11 pmRNSAnnual Financial Report
13th Mar 20267:00 amRNSTransactions in Own Shares
13th Mar 20267:00 amRNSTransactions in Own Shares
12th Mar 20267:00 amRNSTransactions in Own Shares
12th Mar 20267:00 amRNSTransactions in Own Shares
11th Mar 20267:00 amRNSTransactions in Own Shares
10th Mar 20267:00 amRNSTransactions in Own Shares
9th Mar 20267:00 amRNSTransactions in Own Shares
6th Mar 20267:00 amRNSTransactions in Own Shares
5th Mar 20267:00 amRNSTransactions in Own Shares
4th Mar 20264:00 pmRNSDirectorate change
4th Mar 20267:00 amRNSTransactions in Own Shares
3rd Mar 20265:13 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:00 pmRNSHolding(s) in Company
3rd Mar 20267:00 amRNSTransactions in Own Shares
2nd Mar 20261:15 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.